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Mechanism of bicarbonate effect
in CKD
To the Editor: The paper by Mahajan et al.1 describes the
effect of oral sodium bicarbonate (NAHCO3) in slowing
progression over 5 years in patients with hypertensive
nephropathy. However, we were disappointed that the
discussion ‘suggests that the kidney-protective effect of alkali
therapy is through reducing kidney ET production and
tubulointerstitial injury’ and omits any other explanation.
An alternative explanation for these results is that
NAHCO3 reduced intra-tubular complement activation and
thereby slowed progression. This hypothesis was put forth by
Nath and Hostetter,2 who demonstrated a protective effect of
NAHCO3 in the remnant kidney model in rats 25 years ago
and postulated that it reﬂected reduced intratubular comple-
ment activation. We conﬁrmed a functional role of comple-
ment in proteinuric renal disease and in the remnant kidney
model, and showed that it was mediated by C5b-9.3,4
However, none of these (or other) complement-related studies
are cited in the paper, and the complement mechanism is not
mentioned.
It seems likely that there are several mechanisms in play.
For example, just as Mahajan et al. demonstrated a reduction
in urine endothelin excretion in support of the endothelin
hypothesis, Matsuo and colleagues5 showed a reduction in
urinary complement activation products following NAHCO3
administration in proteinuric patients, supporting a comple-
ment-inhibiting effect of NAHCO3.
In our view, as comments on the mechanisms of the
NAHCO3 effect remain entirely speculative in human studies,
readers and future investigators would be better served if all
the mechanisms with strong experimental support were
considered in interpreting the data rather than only one.
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The Authors Reply:We thank Drs Couser and Nangaku1 for
their interest in our recent Kidney International publication2
showing that daily oral NaHCO3 slowed progression of and
reduced kidney injury in subjects with moderately reduced
glomerular ﬁltration rate (GFR) due to hypertensive nephro-
pathy. We agree that our discussion in this publication should
have more extensively included possible explanations for the
reported data other than the endothelin-related mechanisms
that we discussed. Our interest in this clinical area of the
factors that contribute to nephropathy progression grew
from our long-term interest in the mechanisms that mediate
changes in distal nephron acidiﬁcation in response to a
systemic challenge to acid–base status. This interest led to
the identiﬁcation of endothelin as a mediator of the
increased distal nephron acidiﬁcation that occurs in response
to dietary acid.3 From there, our studies progressed to those
showing that endothelin contributes to nephropathy progres-
sion with GFR decline in animals with partial nephrectomy.4
Most recently, we have translated these animal studies
to those in human subjects and have shown that dietary
alkali as Naþ citrate5 and NaHCO3 (ref. 2) slows GFR decline
in subjects with severely and moderately reduced GFR,
respectively, due to hypertensive nephropathy. These latter
two studies in humans support an endothelin role in
nephropathy progression that, we think, relates to the acid
retention state associated with reduced GFR. We have
continued our endothelin-centric focus into our human
studies that developed many years ago as discussed. We
are currently exploring mechanisms other than endothelin
that contribute to progression of human nephropathy
and hope to identify mechanisms that are distinct from
and/or interactive with endothelin in promoting nephro-
pathy progression. In future publications, we will include
reduced complement activation reported by your laboratory6
and earlier by others7 as a possible explanation for the
beneﬁts of dietary alkali on nephropathy progression. We
thank you for pointing out this omission and for giving us
the opportunity to be more inclusive of other mechanisms to
explain the beneﬁts of this possible novel kidney-protective
strategy.
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Phosphorus and coronary
calcification in predialysis patients
To the Editor:We have read the interesting paper of Dr Chiu
et al.1 In a large cohort of proteinuric chronic kidney disease
(CKD) patients with diabetic nephropathy, the authors found
an association between coronary artery calciﬁcation (CAC)
score and risk of death, but they were unable to demonstrate
that CAC score was signiﬁcantly associated to (1) estimated
glomerular ﬁltration rate (eGFR), (2) variables that measure
mineral metabolism and inﬂammation, (3) dyslipidemia. A
similar lack of association between the above variables and
CAC has been previously reported even in non-diabetic CKD
patients (stages 3–5), in whom older age was the unique
predictor factor of CAC.2,3 Taken together, these studies may
indicate that phosphorus is marginally or not at all involved
in the process leading to calciﬁcation. The role of phosphorus
in CAC of CKD patients is ambiguous. On evaluating CAC
progression and its effects on survival, we found that CKD
patients who were not on dialysis and had ‘high–normal’
serum phosphorus levels had faster progression of CAC and
worse survival;3 progression might be slowed down by
phosphorus-binding therapy in the absence of changes in
serum phosphorus concentration.4
More likely, serum phosphorus concentration tells us little
about its balance. In addition, the calciﬁcation process takes a
longer time, while its potential causal factors (particularly
mineral metabolism) rapidly change over time for compen-
satory mechanisms that are mostly active in the early stages of
CKD. Correlating such a long-lasting process with rapidly
ﬂuctuating variables may explain the lack of association.
In the ﬁeld of vascular calciﬁcation, an indicator (such as
glycosylated hemoglobin in diabetics) that gives reliable
information on past ﬂuctuations of the variables that are
potentially involved in the pathogenesis of CAC is needed.
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The Authors Reply: We appreciate Russo et al.,1 for their
insightful remarks and for pointing out the apparent
discrepancy between in vitro and animal studies and that in
humans. Thus, on one hand, cell culture and animal studies
have ﬁrmly established a pivotal role for phosphorus (P) in
the active cell-mediated process of vascular calciﬁcation.2 On
the other hand, as Russo et al.,1 point out, most observational
studies in chronic kidney disease patients have been unable
to show an association between serum P and vascular
calciﬁcation.3,4 Russo et al.,1 rightly urge caution, as a single
measurement of serum P does not provide any information
on the life-time exposure in a given individual. However, we
wish to draw attention to another important issue—the
P present in the blood is o1% of the total body P. It
is conceivable that—though presently not known—an
individual may achieve a signiﬁcant positive P balance
without a signiﬁcant change in its serum levels. P binder
may mitigate the positive P balance without changing serum
P levels—it may be for this reason that they were able to
attenuate vascular calciﬁcation. Notwithstanding the limita-
tions of serum P, the importance of P in inducing or
worsening vascular calciﬁcation in humans can be deﬁnitively
answered only by interventional studies, in which subjects are
randomized to two different levels of serum P.
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